Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
about
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusLinagliptin use in older individuals with type 2 diabetesDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsSafety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.Optimal therapy of type 2 diabetes: a controversial challengeChallenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspectiveComparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonAchieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Diabetes: glycaemic control in type 2 (drug treatments).Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review.Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyClinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitusEfficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting.Management of type 2 diabetes mellitus in older adults.Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptinCost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand.Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during RamadanThe dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Vildagliptin in clinical practice: a review of literature.DPP-4 inhibitors in clinical practice.Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.Vildagliptin in the treatment of type 2 diabetes mellitus.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.Clinical management of elderly patients with type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.Drug-induced hypoglycaemia in type 2 diabetes.Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate.Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.HTA agencies facing model biases: the case of type 2 diabetes.Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.
P2860
Q24235718-17802679-D705-4767-9AAB-AB806577CBE1Q24240522-28A0C224-CCF0-4821-B65F-56B90AD29456Q26825033-274D5A62-93B6-4AE5-A6E6-81136F8A2075Q28238585-AC82F854-D706-4A66-B325-D28707A894BBQ28294225-6F64564C-8992-4F63-AE3E-2DA50863A89FQ30827022-4C92F46F-3DA2-4BC7-A47F-C989FAFEF3F8Q33577712-AC36F4E7-47B2-474B-9E8A-519A649499E2Q33587783-1E1184AA-0BCB-441C-A74F-1FA38F4358ABQ33785197-F7E799C8-46F2-4A37-A279-BFFBF66C9EBCQ34563587-D8AE0434-571A-43EA-94CB-DA14907AA967Q34829290-5EF56FEE-2583-4588-BD6C-6EA845623825Q35236019-BC563B6E-0465-48CA-B3D8-3668214CD86BQ35541829-3E950790-1697-43B7-A99D-A05556271F48Q35688369-01763875-842F-460C-AAC8-BEEABF6AA95CQ35717211-53E82117-905D-4213-8143-21C7037591F1Q35997324-B9419F51-8C35-4B6E-8C98-18C1F28F7266Q36041081-4F4E1AA5-CC1F-469F-8C89-8F1376411CC8Q36365216-456F6FB4-FFB2-4FCB-A09A-3377555F5A07Q36574084-FD0FC1D3-136D-4D9C-AF5D-6833B2360002Q36785098-26749ABB-991C-456C-A022-2D780C0461FDQ36805122-8D306CB3-204B-4396-803B-C7BDB81EA3FEQ37284014-031BB8BF-7488-4A5A-BD60-7C72B43E2AB5Q37346737-7DF59946-FE4B-4FE8-88F6-8E65949EFFDDQ37417767-F3286E6C-6422-4300-9C42-B4285EE2EB95Q37502682-8C8D1083-EDC3-4F0C-8B71-B1A4F1A29491Q37623831-FFE632A7-CDDF-4163-A797-9DA05F061CEDQ37638984-83851E8F-0ADA-4821-A7C6-27E4863F0C44Q37825941-FB65BF87-2867-4E26-8F93-EADF1B9AA360Q37858364-3EB06C80-51C3-42AC-AE6B-BDC29A5AF2C4Q37890411-AAE04594-A801-45DE-B82B-B3EA77132ACFQ37910902-3E60FBF9-6939-4509-8D59-6C7E9CF8EB0CQ37970749-26714351-18EB-463B-812E-38755F2EC63EQ37982214-5628D146-BA98-4C94-81EC-6A031B3AF18FQ37992956-9D735754-6D85-4CFC-BC30-BAE5E11CE9DBQ38004088-78E2B8ED-E4C7-47CB-BCF2-29CA96CD9CA9Q38018110-09405602-3BD3-4FB0-9CE2-F7657E154D0FQ38200923-D6EF3B10-18E5-4343-9285-ABFFEB3205C9Q38212472-001BC869-9EC2-49BE-AE8D-7899365216E2Q38215010-16BDDE48-26A0-4FA5-990A-D7046862B989Q38215452-6EDC9F6C-AA01-466D-BA0B-85D50D4DB3E3
P2860
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Comparison of vildagliptin and ...... ouble-blind, randomized trial.
@en
Comparison of vildagliptin and ...... ouble-blind, randomized trial.
@nl
type
label
Comparison of vildagliptin and ...... ouble-blind, randomized trial.
@en
Comparison of vildagliptin and ...... ouble-blind, randomized trial.
@nl
prefLabel
Comparison of vildagliptin and ...... ouble-blind, randomized trial.
@en
Comparison of vildagliptin and ...... ouble-blind, randomized trial.
@nl
P2093
P1476
Comparison of vildagliptin and ...... ouble-blind, randomized trial.
@en
P2093
P304
P356
10.1111/J.1463-1326.2009.01051.X
P577
2009-05-19T00:00:00Z